Skip to main content

Day: December 29, 2020

Regarding the rebuttal of information provided about the long-term motivation with share option agreement programme of key executives of AB “Ignitis grupė” group of companies published by VšĮ “Lietuvos nacionalinis radijas ir televizija”

On 29 December 2020 a VšĮ “Lietuvos nacionalinis radijas ir televizija” (hereinafter – LRT) published in their news portal a misleading and false information in the audio reporting Sočios šventės “Ignitis grupės” vadovams: dykai gaus akcijų už 200 tūkstančių eurų (Translation: Filling holidays for executives of Ignitis Group: will get shares for 200,000 euros gratis) by LRT journalist Marius Jokūbaitis (hereinafter – the Publication), where it provided information about the long-term motivation with share option agreement programme of key executives of AB “Ignitis grupė” group of companies.AB “Ignitis grupė” (hereinafter – Ignitis Group or the Company) states that the Publication creates a false and biased impression of the long-term motivation with share option agreement programme for the key executives of the Ignitis Group group of...

Continue reading

Dėl VšĮ „Lietuvos nacionalinis radijas ir televizija” pateiktos informacijos apie AB „Ignitis grupė“ įmonių grupės pagrindinių vadovų ilgalaikio skatinimo akcijų opcionais programą, paneigimo

2020 m. gruodžio 29 d. VšĮ „Lietuvos nacionalinis radijas ir televizija” (toliau – LRT) garso reportaže skleistoje ir interneto svetainėje patalpintoje publikacijoje „Sočios šventės „Ignitis grupės“ vadovams: dykai gaus akcijų už 200 tūkstančių eurų“ (toliau kartu – Publikacija), kurios autorius LRT žurnalistas Marius Jokūbaitis, pateikiama informacija apie AB „Ignitis grupė“ įmonių grupės pagrindinių vadovų ilgalaikio skatinimo akcijų opcionais programą.AB „Ignitis grupė“ (toliau – „Ignitis grupė“ arba Bendrovė) pareiškia, kad nurodytoje Publikacijoje kuriamas klaidingas ir šališkas įspūdis apie „Ignitis grupės“ įmonių grupės pagrindinių vadovų ilgalaikio skatinimo akcijų opcionais programą.„Ignitis grupė“, siekdama, kad Publikacija neklaidintų investuotojų, visuomenės ir kitų rinkos dalyvių, skelbia Publikacijoje pateiktų tikrovės neatitinkančių...

Continue reading

Alico, Inc. to Present at 23rd Annual ICR Conference

FORT MYERS, Fla., Dec. 29, 2020 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that John Kiernan, the Company’s President and Chief Executive Officer, will present at the 23rd Annual ICR Conference to be held virtually January 11-14, 2021.The Company’s presentation will begin at 8:30 am Eastern time on Tuesday, January 12, 2021. The Company will be participating in virtual one-on-one and small group meetings.About AlicoAlico, Inc. primarily operates two divisions: Alico Citrus, one of the nation’s largest citrus producers, and Alico Land Management and Other Operations, which include environmental services, land leasing and related support operations. Learn more about Alico (Nasdaq: “ALCO”) at www.alicoinc.com.Investor Contact:Investor Relations(646) 277-1254InvestorRelations@alicoinc.comRichard...

Continue reading

QuestCap Announces Name Change to Medivolve Inc.

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce that the Company has changed its name to “Medivolve Inc.” (“Medivolve”) in conjunction with its transition to a single purpose medical company, previously announced on October 13, 2020. Subject to approval of the NEO Exchange (“NEO”), trading of the Company’s shares under the new name and new ticker “MEDV” on the NEO is expected to commence on January 7, 2021.This name change emphasizes QuestCap’s new standing as a medical services and technology company. Moving forward, the QuestCap team will focus exclusively on developing and implementing innovative medical solutions across the globe, with a short-term focus on combatting the COVID-19 pandemic and helping restore reality responsibly.The Company’s...

Continue reading

Kratos Awarded Contract Modification Valued at $22 Million to Provide Satellite Command and Control System Sustainment

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has received a delivery order valued at $22 million and funded at $11.8 million for satellite and communication system products, hardware and equipment. This modification is against a previously-awarded contract.This award is for mission activity and maneuver planning, telemetry processing, commanding, orbit and attitude management, resource management, space vehicle and ground system simulation, security, support planning and execution, training and testing. The modification will now sustain new capability such as virtualization, additional satellite constellation capacity and cybersecurity enhancements. Satellite state-of-health operations include launch,...

Continue reading

Par Pacific Holdings Management to Participate in Virtual Investor Conferences

HOUSTON, Dec. 29, 2020 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific”) today announced that members of its management team will present at the 3rd Annual Mizuho Virtual Refining Conference on January 5, 2021 at 1:00 pm CT. They will also participate in a panel discussion at the Goldman Sachs Global Energy Conference 2021 on January 7, 2021 at 9:30 am CT and host 1×1 sessions with investors throughout the day. The most current investor presentation is available on the investor relations section of Par Pacific’s website at www.parpacific.com.About Par PacificPar Pacific Holdings, Inc. (NYSE: PARR), headquartered in Houston, Texas, owns and operates market-leading energy, infrastructure, and retail businesses. Par Pacific’s strategy is to acquire and develop businesses in logistically complex markets. Par...

Continue reading

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.ITI-333 introduces a unique pharmacology for the treatment of opioid use disorder.NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the initiation of clinical programs for the Company’s lumateperone long-acting injectable formulation (ITI-LLAI) and for ITI-333, a novel molecule for the treatment of opioid use disorder.“I am pleased to announce that two important proprietary programs have advanced into human clinical testing, further demonstrating our commitment to patients through the development of...

Continue reading

Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year

TEMPLE CITY, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has extended its partnership with the New York City Department of Education (or “NYC DOE”) and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.Through the agreement, Fulgent will provide COVID-19 testing for thousands of students and employees at many K-12 schools in New York City on a daily basis.  The NYC DOE will leverage Fulgent’s FDA EUA-approved...

Continue reading

BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1×1 meetings. The BeyondSpring leadership team also will be available for one-on-one meetings during the LifeSci Advisors Corporate Access Event on January 7-8 and 11-13, 2021.Details for both events are as follows:39th Annual J.P. Morgan Healthcare Conference (Corporate Presentation)2021 LifeSci Advisors Corporate Access EventA video replay of the JPM presentation will be available on the Events and Presentations section investor...

Continue reading

POET Technologies to Present at the Needham Growth Conference on January 14

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that Vivek Rajgarhia, President and General Manager, and Thomas Mika, Executive Vice President & Chief Financial Officer, will participate at the Needham Growth Conference, which will be held as a virtual event. Management is scheduled to present at 4:15 p.m. ET on Thursday, January 14, 2021 and will be available throughout the day to meet with investors attending the conference.Portfolio managers and analysts who would like to request a meeting with management should email conferences@needhamco.com or contact their Needham representative....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.